Patents Assigned to Inserm
  • Vector particles for targeting CD34+ cells
    Patent number: 9714434
    Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and a second protein which comprises a ligand of the c-Kit receptor.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 25, 2017
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Francois-Loic Cosset, Els Verhoeyen, Caroline Costa, Cecilia Frecha
  • Carboline compounds usable in the treatment of neurodegenerative diseases
    Patent number: 9714245
    Abstract: The present invention relates to a compound according to Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, and its use.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: July 25, 2017
    Assignees: ALZPROTECT, UNIVERSITE DE LILLE 2 DROIT ET SANTE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Patricia Melnyk, Pascal Carato, Stephane Burlet, Emilie Nguyen, Philippe Verwaerde, Nicolas Sergeant, Cecilia Estrella
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF OREXIN-1 RECEPTOR OX1R FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
    Publication number: 20170202925
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
    Type: Application
    Filed: June 23, 2015
    Publication date: July 20, 2017
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT - PARIS 7, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Alain COUVINEAU, Thierry VOISIN, Nassima MESSAL, Eric OGIER-DENIS, Xavier TRETON
  • Methods for stimulating antigen-specific T cell responses
    Patent number: 9708583
    Abstract: The present invention relates to methods for stimulating antigen-specific T cell responses. In particular, the invention relates to a method for stimulating antigen (Ag)-specific T cell responses in a blood sample or PBMC sample isolated from a subject comprising the step consisting in culturing said blood or PBMC sample in a appropriate culture medium which comprises an amount of IL-1beta and an amount of a least one antigen.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: July 18, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventors: Roberto Mallone, Georgia Afonso
  • Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
    Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • Methods for producing a population of pancreatic beta-cells
    Patent number: 9708608
    Abstract: The present invention relates to an in vitro or ex vivo method for producing a population of pancreatic beta-cells, comprising the step of inhibiting the expression or the activity of Arx in a population of pancreatic alpha-cells. The present invention also relates to method for inducing the conversion of pancreatic alpha-cells in pancreatic beta-cells in a patient in need thereof.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: July 18, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientific (CNRS), Universite Nice Sophia Antipolis
    Inventors: Patrick Collombat, Keith Al-Hasani, Monica Courtney, Nouha Ben-Ohtman, Elisabet Gjernes, Ahmed Mansouri
  • Hydrophobically modified antisense oligonucleotides comprising a ketal group
    Patent number: 9701962
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 11, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE BORDEAUX, UNIVERSITE D 'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • METHOD FOR PRODUCING METHANE BY MEANS OF AEROBIC CO-CULTURE OF ANAEROBIC MICRO-ORGANISMS
    Publication number: 20170191084
    Abstract: The present invention relates to the biological production of methane (Biogas) by co-culture in an aerobic atmosphere of a methanogenic bacterium and of an anaerobic bacterium capable of producing hydrogen, in a culture medium comprising or being supplemented with carbohydrate compound(s), notably starch and/or sugars, and supplemented with antioxidant compound(s).
    Type: Application
    Filed: April 20, 2015
    Publication date: July 6, 2017
    Applicants: FONDATION MEDITERRANEE INFECTION, UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Didier RAOULT, Saber KHELAIFIA, Michel DRANCOURT
  • Antibodies directed against ICOS for treating graft-versus-host disease
    Patent number: 9695247
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: July 4, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITÉ D'AIX-MARSEILLE
    Inventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
  • Direct protein delivery with engineered microvesicles
    Patent number: 9695446
    Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: July 4, 2017
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau
  • USE OF URIC ACID FOR CULTURING BACTERIA SENSITIVE TO OXYGEN TENSION
    Publication number: 20170183620
    Abstract: The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and said bacterium is cultivated in said culture medium in the presence of oxygen.
    Type: Application
    Filed: April 21, 2015
    Publication date: June 29, 2017
    Applicants: FONDATION MEDITERRANEE INFECTION, UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Didier RAOULT, Saber KHELAIFIA, Michel DRANCOURT
  • Methods and Compositions for Treating Neuropathic Pain
    Publication number: 20170183662
    Abstract: The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct administration into the peripheral nervous system (PNS) of a patient (e.g., formulated for intrathecal administration).
    Type: Application
    Filed: July 8, 2015
    Publication date: June 29, 2017
    Applicants: INSERM (Institut National de la Sante et de lA Recherche Medicale, Universite de Montpellier
    Inventors: Patrick Carroll, Alexandre Pattyn, Stephanie Venteo
  • METHOD FOR OBTAINING A FUNCTIONAL PARAMETER OF A MUSCLE
    Publication number: 20170181729
    Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.
    Type: Application
    Filed: July 17, 2015
    Publication date: June 29, 2017
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITÉ PARIS DIDEROT - PARIS 7, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Mickael TANTER, Mathieu PERNOT
  • CYCLIC COMPOUNDS HAVING A 1,3 DIAMINO-FUNCTIONALITY FOR USE IN THE TREATMENT OF HIV INFECTION
    Publication number: 20170183306
    Abstract: The present invention relates to compounds, capable of activating HIV expression in reservoir cells, of formula (I) for use in the treatment of HIV infection.
    Type: Application
    Filed: May 29, 2015
    Publication date: June 29, 2017
    Applicants: Universite Paris Decartes, Centre National de la Recherche Scientifique (CNRS), Universite Pierre et Marie Curie (Paris 6), Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris
    Inventors: Laurent Micouin, Aurélie Blond, Vincent Calvez, Anne-Geneviève Marcellin, Cathia Soulie, Emilie Corrot
  • METHODS FOR PREDICTING THE SURVIVAL TIME OF PATIENTS SUFFERING FROM CANCER
    Publication number: 20170183742
    Abstract: The present invention relates to methods for predicting the survival time of patients suffering from cancer. Said methods are based on the quantification and analysis of the cell free nucleic acids that are present in a sample from the patient and typically include the determination of the level of the mutant nucleic acid which contains a mutation of interest, the calculation of the mutation load for said mutation of interest, the calculation of the DNA integrity index or a combination thereof.
    Type: Application
    Filed: May 27, 2015
    Publication date: June 29, 2017
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Alain THIERRY, Safia MESSAOUDI, Florent MOULIERE
  • Methods and pharmaceutical compositions for treatment of cystic fibrosis
    Patent number: 9688990
    Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: June 27, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Montpellier
    Inventor: Magali Taulan-Cadars
  • Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
    Patent number: 9688767
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 27, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Universite Pierre et Marie Curie-UPMC, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
    Patent number: 9688742
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: June 27, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITE PARIS DIDEROT—Paris 7
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders
    Publication number: 20170176417
    Abstract: The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 22, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Ludivine Perrocheau, Alain Van Dorsselaer, Jose Alain Sahel, Thierry Leveillard
  • METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION
    Publication number: 20170175207
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN